ScholarWorks@Hanyang University: Kim, Bongyoung

Detailed Information

Kim, Bongyoung (김봉영)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 항생제 스튜어드십, 항생제 내성, 요로감염, Antimicrobial Stewardship Program, Antimicrobial Resistance, Urinary Tract Infection

Tel 02-2290-8357
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Korea:26||Antibiotics:9||COVID19:9||Stewardship:8||Urinary tract infection:7||Resistance:6||Antimicrobial resistance:6||South Korea:5||Clostridioides difficile:4||Antibacterial agents:4||Hospital:4||Acute pyelonephritis:4||antibiotics:4||Antibiotic consumption:3||SARSCoV2:3||Hospitals:3||pyelonephritis:3||Antimicrobial Stewardship:3||Antimicrobial stewardship:3||fluoroquinolone:3||Escherichia coli:3||Bacteria:2||Drug resistance:2||coronavirus:2||Antibiotic prophylaxis:2||Antimicrobial:2||Infectious diseases:2||stewardship:2||Epidemiology:2||Psychological distress:2||Pyelonephritis:2||urinary tract infection:2||Workforce:2||Infection control:2||Quality indicator:2||Accreditation:2||Appropriateness:2||extended care facilities:2||Guidelines:2||Consensus:2||Bacteroides thetaiotamicron:2||Benchmarking:2||ST131:2||isolation:2||Burnout:2||Leadership:2||Bacterial infection:2||Communityacquired pneumonia:1||Coronavirus Disease 2019:1||Coronavirus disease 2019:1||Correlation:1||Delta variant:1||Diabetes:1||Distribution:1||E:1||EMT:1||ESRD:1||Emerging:1||Expert:1||Expert opinion:1||Extendedspectrum betalactamase:1||Extrapulmonary:1||Fever:1||Financial Support:1||Financial support:1||Focus Groups:1||Foreleg raising power:1||HIV:1||Health Facilities:1||Health Workforce:1||Healthcareassociated infection:1||Heart failure:1||Hepatitis A:1||Hospitalization:1||Human immunodeficiency virus:1||Human immunodeficiency virus (HIV):1||Inappropriate:1||Incidence:1||Infection:1||Infection Control:1||Infectious:1||Infectious Disease Specialists:1||Infectious Diseases:1||Infectious diseases medicine:1||Infective endocarditis:1||Ischemic heart disease:1||KOICA:1||KONAS:1||Lymphadenopathy:1||MIC:1||MLVA:1||Male:1||Measurement:1||Mediastinitis:1||Medical costs:1||Megaloblastic anemia:1||Metronidazole:1||Microbial:1||Minimum inhibitory concentration:1||MixandMatch:1||Monitoring:1||Mortality:1||Multidisciplinary:1||Multidisciplinary communication:1||Multidisciplinary communications:1||National Action Plan:1||National Health Insurance:1||National health insurance:1||Nationwide observation study:1||Nationwide survey:1||Negativepressure wound thearpy:1||Neuromuscular blocking agent:1||Nodular:1||Omicron variant:1||PCR ribotype:1||Paralysis:1||Paramedics:1||Pediatrics:1||Peru:1||Physicians:1||Pig:1||Piperacillin/tazobactam:1||Pneumocystis jirovecii:1||Pneumonia:1||Point prevalence survey:1||Porphyromonas pogonae:1||Postacute COVID19 syndrome:1||Prescription:1||Prescriptions:1||Professional Development:1||Prosthetic valve:1||Pseudomonas aeruginosa:1||Psychological:1||Qualitative assessment:1||Quality assessment of antibiotic use:1||Quarantine:1||Radiography:1||Recurrent:1||Republic of Korea:1||Respiratory function tests:1||Retropharyngeal abscess:1||Ribotype:1||Risk factor:1||Rothia mucilaginosa:1||SAAR:1||SARS:1||Scrub typhus:1||Selfcontrolled case series:1||Sion 's local paralysis:1||Soft tissue infection:1||Succinylcholine:1||Surveys and Questionnaires:1||Terminally Ill:1||Tigecycline:1||Transmission:1||Treatment:1||Tsh:1||Vaccine:1||Vaccine safety:1||Vacuumassisted closure:1||Vancomycin:1||Virulence factors:1||Vitamin B12:1||Wholegenome sequencing:1||adult:1||aminoglycoside:1||antibacterial agents:1||antibiotic resistance:1||antibiotic resistance genes:1||antibiotic use:1||antibody level:1||antimicrobial resistance:1||antimicrobial stewardship:1||bacterial composition:1||children:1||coli:1||coronavirus disease:1||correlation:1||diabetes complications:1||education:1||empiric antibiotic therapy:1||genetic relatedness:1||gut microbiome:1||health insurance:1||health professionals:1||international cooperation doctors:1||medical student:1||melioidosis:1||neurological outcomes:1||outofhospital cardiac arrest:1||outpatients:1||piperacillin/tazobactam:1||pregnancy:1||prognosis:1||resistance:1||respiratory infections:1||ribotype 017:1||severe acute respiratory syndrome coronavirus 2:1||statistical model:1||targeted temperature management:1||thoracic:1||treatment:1||viruses:1||zoonoses:1||다발성 골수종:1||다학제:1||리더십:1||의료기관 인증:1||재정적 지원:1||항생제 내성:1||혐기성 세균:1||2015:1||화 농성 관절염:1||2019 novel coronavirus disease:1||AIDS:1||AWaRe:1||Acinetobacter baumannii:1||Acinetobacter infections:1||Acquired immune deficiency syndrome:1||Acute Pyelonephritis:1||Adrenal Insufficiency:1||Adult:1||Anaerobe:1||Anaerobic:1||AntiBacterial Agents:1||AntiInfective Agents:1||AntiInfective agents:1||Antibacterial agents:1||Antibiotic:1||Antibiotic Consumption:1||Antibiotic resistance:1||Antibiotic stewardship:1||Antibiotic use:1||Antibodies:1||Antibody Level:1||Antimicrobial Agents:1||Antimicrobial Stewardship Programs:1||Antimicrobial drug resistance:1||Antimicrobial stewardship program:1||Antimicrobial use:1||Antimicrobials:1||Antiviral:1||Applicability:1||Arthritis:1||Asymptomatic bacteriuria:1||Atrial fibrillation:1||Atypical:1||Burkholderia pseudomallei:1||COVID19 Vaccines:1||COVID19 breakthrough infection:1||COVID19 vaccines:1||Carbapenem:1||Cerebral hemorrhage:1||Clostridioides difficile infection:1||Colonization:1||Combination drug therapy:1||Communicable Diseases:1||Communicable diseases:1||Community acquired:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE